Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Capital Goods
/
JBT Marel
JBTM
JBT Marel
Alternative Proteins And Integration Setbacks Will Squeeze Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
11 Jul 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$88.23
59.0% overvalued
intrinsic discount
09 Aug
US$140.33
Loading
1Y
57.0%
7D
4.2%
Author's Valuation
US$88.2
59.0% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$88.2
59.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-138m
4b
2014
2017
2020
2023
2025
2026
2028
Revenue US$4.4b
Earnings US$491.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.87%
Machinery revenue growth rate
0.29%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.57%
Calculation
US$490.98m
Earnings '28
x
14.51x
PE Ratio '28
=
US$7.12b
Market Cap '28
US$7.12b
Market Cap '28
/
63.82m
No. shares '28
=
US$111.59
Share Price '28
US$111.59
Share Price '28
Discounted to 2025 @ 8.61% p.a.
=
US$87.09
Fair Value '25
